NFKB1 and Mental deterioration: Animal experiments have shown that dexmedetomidine can reduce the inflammatory response by reducing IL-1β and NF-κB levels via α2 adrenoceptors, thereby improving the cognitive decline caused by inflammation (Li et al., 2020).